BBS-Bioactive Bone Substitutes Plc Applies for The
BBS-Bioactive Bone Substitutes Oyj, Company release, 13 February 2023 at 11.00 am EET
BBS-Bioactive Bone Substitutes Applies for The Delisting of Secondary Listing on Nasdaq First North Growth Market Sweden
Following the earlier announcement made on 4 November 2022, BBS-Bioactive Bone Substitutes Oyj (“BBS”) has today applied for the delisting of its shares from Nasdaq First North Growth Market Sweden (“Nasdaq FN GM Sweden”).
The Board of directors has taken into account the low level of trading activity of the Company's shares since its listing on the Exchange in 2018, as well as the limited number of shareholders registered with Euroclear Sweden AB. The Board has also evaluated the additional expenses associated with maintaining a secondary listing for a company of its size and the administrative responsibilities entailed by complying with the listing requirements of multiple markets.
The Company wants to remind BBS’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of BBS’ shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in BBS’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy. To effectuate cross-border settlement, the shareholder should contact their respective custodian. Some custodians will automatically do the settlement, and others will activate the cross-border settlement after approval by the shareholder.
The Company expects the final day of trading on Nasdaq First North Growth Market Sweden to occur on 6 March 2023. BBS will provide additional details regarding the delisting following a decision from Nasdaq Sweden on the application.
Following the delisting from Sweden, BBS-Bioactive Bone Substitutes’s shares will be traded solely on Nasdaq First North Growth Market Finland in Euro and under the trading code: BONEH (ISIN code: FI4000260583).
For more information:
Ilkka Kangasniemi, CEO,
tel. +358 40 708 0307, e-mail: email@example.com
Nordic Certified Adviser AB, tel. +46 70 551 67 29, firstname.lastname@example.org
BBS in brief
BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.
BBS-Bioactive Bone Substitutes Oyj:n shares are listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden (until delisting).
More information: www.bbs-artebone.fi
- HUYA Inc. Reports Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results
- How do I find the best sourcing agents in Vietnam?
- EVN asked to buy renewable energy at 90% import price
- Haleon launches #BetterOralCareNation campaign to improve oral health habits in Malaysia
- SBV tightens control on corporate bond acquisitions by banks
How do I find the best sourcing agents in Vietnam?
Breaking News: Vingroup’s Shocking Move to Revolutionize Taxi Industry with Electric Cars – Be Group Partnership Revealed!
Shares open new week on negative note amid uncertainty
What to know about the new Malaysian CEO of Vietnamese property developer Novaland
Careful action required to curb inflation threat